The proprietary Hemostemix technology encompasses 1) a population of cells named the synergetic cell population (SCP) that is derived from a simple blood draw, similar to a blood donation; 2) the process of isolating those cells; and 3) the enrichment and differentiation of those cells into various cell lineages. The end product is a mixture of cells packaged in ready-to-use syringes. 

Our team has been able to take advantage of the potential of this cell population and to differentiate it into a variety of cell types including angiogenic cell precursors, or ACPs. These are cells capable of forming or supporting the formation of new blood vessels. 

ACPs share features that are similar to those of endothelial progenitor cells (EPCs). ACPs secrete tissue survival- and regeneration-supporting growth factors and cytokines that facilitate the formation of blood vessels through vasculogenesis and angiogenesis. Factors secreted by ACPs also facilitate the recruitment of additional progenitor cells to promote the healing of damaged tissues.

We have now successfully completed three clinical trials with ACP-01, one in angina pectoris and two in critical limb ischemia. Additionally, from 2005 to 2009, the product was used on a compassionate-use basis for the treatment of several hundred patients with no reports of treatment-related adverse events or safety concerns.